Loading…
Cancer Drug Coverage Parity Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Cancer Drug Coverage Parity Act of 2015 This bill amends the Public Health Service Act to require a group or individual health plan that covers anticancer medications administered by a health care provider to provide no less favorable coverage for anticancer medications administered by a patient. A plan may apply to patient-administered anticancer medications only the cost-sharing and limitations that apply to anticancer medications administered by a health care provider. These requirements apply to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration. To comply with these requirements, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (18)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2017 · first_quarter · Health Issues
- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.
Client expense: $1,030,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
Biosimilars (FDA); ACA implementation; HR 2739/S 1566 - Cancer Drug Coverage Parity Act; HR 1313 Preserving Employee Wellness Programs Act; HR 1628 American Health Care Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
HR 2739 / S 1566, the Cancer Drug Coverage Parity Act of 2015 - insurance coverage equality for oral anticancer medications
Client expense: $45,703 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Budget/Appropriations
HR 2739 and S. 1566 Cancer Drug Coverage Parity Act
Client expense: $45,703 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.
| Republican |
| LA |
| Charles E. Schumer | Democratic | NY |
| Christopher A. Coons | Democratic | DE |
| Christopher Murphy | Democratic | CT |
| David Vitter | Republican | LA |
| Edward J. Markey | Democratic | MA |
| Elizabeth Warren | Democratic | MA |
| Jeff Merkley | Democratic | OR |
| Kirsten E. Gillibrand | Democratic | NY |
| Lisa Murkowski | Republican | AK |
| Michael F. Bennet | Democratic | CO |
| Richard Blumenthal | Democratic | CT |
| Roger F. Wicker | Republican | MS |
| Sheldon Whitehouse | Democratic | RI |
| Sherrod Brown | Democratic | OH |
| Susan M. Collins | Republican | ME |
| Tammy Baldwin | Democratic | WI |
| Thad Cochran | Republican | MS |
Client expense: $1,640,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2016 · fourth_quarter · Health Issues
Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
HR 2739 / S 1566, the Cancer Drug Coverage Parity Act of 2015 - insurance coverage equality for oral anticancer medications
Client expense: $42,005 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
HR 2739 / S 1566, the Cancer Drug Coverage Parity Act of 2015 - insurance coverage equality for oral anticancer medications
Client expense: $45,703 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Budget/Appropriations
HR 2739 and S. 1566 Cancer Drug Coverage Parity Act
Client expense: $45,703 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
HR 2739 / S 1566, the Cancer Drug Coverage Parity Act of 2015 - insurance coverage equality for oral anticancer medications
Client expense: $45,703 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
S. 524 Comprehensive Addiction and Recovery Act of 2016 Senate HELP Committee Innovations Package HR 6 21st Century Cures Act HR 1600 Patients Access to Treatment Act of 2015 HR 2739/S 1566 Cancer Drug Coverage Parity Act HR 3381/S 1883 Childhood Cancer STAR Act HR 3119 Palliative Care Hospice Education and Training Act S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015 H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015 S. 2511 Improving Health Information Technology Act Reforms to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
Client expense: $65,519 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the Patient Protection and Affordable Care Act. Policy and implementation issues relating to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the Food and Drug Administration Amendments Act, specifically FDA's Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 34, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S. 1566, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Client expense: $740,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Insurance
H.R. 30, Save American Workers Act (Young) - definition of full-time employee H.R. 117, Reclaiming Individual Liberty Act (Garrett) - ACA individual mandate H.R. 221, ACA Taxpayer Bailout Prevention Act (Harris) - risk corridors program H.R. 371, Care for All Act (Fortenberry) - catastrophic plans H.R. 494, Competitive Health Insurance Reform Act (Gosar) - antitrust policy H.R. 543, Health Care Choice Act (Blackburn) - national marketplace for individual health insurance H.R. 724, Taxpayer Bailout Protection Act (Lance) - risk corridors program H.R. 815, Access to Independent Health Insurance Advisors Act (Long-Schrader) - treatment of broker compensation in MLR calculation H.R. 954, CO-OP Consumer Protection Act (Smith) - exemption from individual mandate H.R. 1770, Data Security and Breach Notification Act (Blackburn-Welch) - data security H.R. 2205, Data Security Act (Neugebauer) - data security H.R. 2739, Cancer Drug Coverage Parity Act (Lance) - coverage of oral anti-cancer drugs H.R. 2868, Small Business Health Fairness Act (Johnson) - association health plans H.R. 3323, Dental and Optometric Care Access Act (Carter) - dental and vision benefits H.R. 3727, Health Insurance Rate Review Act (Schakowsky) - rate review H.R. 4299, Patient Opportunity Protection Act (Blum) - HIPAA excepted benefits H.R. 5410, Health Coverage State Flexibility Act (Flores) - grace period for recipients of advanced premium tax credits H.R. 5589, Plan Verification and Fairness Act (Blackburn) - pre-enrollment verification process H.R. 5921, State Age Rating Flexibility Act (Bucshon) - age rating flexibility H.R. 6019, Relief from Obamacare Mandate Act (Young) - exemption from individual mandate H.R. 6049, Protection from Insurance Exchange Monopolies Act (Heck) - exemption from individual mandate H.R. 5926, FY 2017 Labor-HHS-Education Appropriations Bill (Cole) - ACA risk corridors provision, HHS appropriations H. Res. 887, Public Option (DeFazio) S. 30, Forty Hours Is Full Time Act (Collins) - definition of full-time employee S. 123, ACA Taxpayer Bailout Prevention Act (Rubio) - risk corridors program S. 158, Employee Health Care Protection Act (Cassidy) - grandfathering of health coverage S. 359, Taxpayer Bailout Protection Act (Cassidy) - risk corridors program S. 1099, Protecting Affordable Coverage for Employees Act (Scott-Shaheen) - ACA definition of small employer S. 1532, Affordability is Access Act (Murray) - coverage of OTC birth control S. 1566, Cancer Drug Coverage Parity Act (Kirk) - coverage of oral anti-cancer drugs S. 1661, Access to Independent Health Insurance Advisors Act (Isakson-Coons) - treatment of broker compensation in MLR calculation S. 2172, Health Insurance Rate Review Act (Feinstein) - rate review S. 2803, Taxpayers Before Insurers Act (Sasse) - ACA reinsurance program S. 3296, Protection from ObamaCare Monopolies Act (McCain) - exemption from individual mandate S. 3297, Relief from Obamacare Mandate Act (Cotton) - exemption from individual mandate S. 3326, State Flexibility to Provide Affordable Health Options Act (Alexander) - ACA subsidies, exemption from individual mandate S. Res. 561, Public Option (Merkley) Regulatory Issues: Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; disability income insurance enrollment and awareness; issues related to encouraging impaired workers to stay in/return to the workforce; issues relating to the coordination of benefits between private health insurance plans and Medicaid; Medigap claims processing and crossover fees; Medigap cross-over claim issues, Medigap coverage, implementation of Medigap standardized plan offerings; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials, and other Medigap issues; fraud and abuse issues affecting public and private insurance coverage; issues relating to antitrust; implementation of the Mental Health Parity Act requirements; summary of benefits and coverage disclosures; pre-existing condition insurance plans; accountable care organizations; coverage of preventive services; preexisting condition exclusions; lifetime and annual dollar limits on benefits; patient protections; grandfathered health plan provisions; dependent coverage; treatment of expatriate plans; compliance with the transitional reinsurance program; issues related to fraud, waste, abuse, Stark/Anti-Kickback laws and regulations, non-discriminatory wellness programs; issues related to supplemental products; issues related to implementation of the Telephone Consumer Protection Act; issues relating to third party payment of premiums; and other issues relating to health care reform implementation.
Client expense: $1,330,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Treasury, Dept of, White House Office
2016 · fourth_quarter · Health Issues
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Client expense: $510,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
General FDA issues; S 1566/HR 2739 Cancer Drug Coverage Parity Act; S 3056 CREATES Act; HR 2841 FAST Generics Act. 21st Century Cures legislation (HR6/HR 34)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.
Client expense: $1,620,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2016 · fourth_quarter · Health Issues
Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.
Client expense: $1,630,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2016 · fourth_quarter · Health Issues
Pub. Law No. 111-148, Patient Protection and Affordable Care Act, matters related to the implementation of breast health education, research and clinical trials; S.1566/H.R.2722, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients; H.R.1600, Patients' Access to Treatment Act, support amending the Public Health Service Act to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure and prohibits such a health plan from imposing higher cost-sharing requirements, including co-payment and co-insurance, for specialty drugs than for other prescription drugs in a non-preferred brand drug tier; H.R.1608, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; S.370/H.R.716, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; H.R.1925, Dr. Balazs "Ernie" Bodai Congressional Gold Medal, support the presentation of a congressional gold medal to Dr. Balaz "Ernie" Bodai in recognition of his many outstanding contributions to the nation, including a tireless commitment to breast cancer research; H.R.6, 21st Century Cures Act, issues related to cancer prevention and research funding; S.620/H.R.1189, Preserving Employee Wellness Programs Act, issues related to the Genetic Information Act of 2008 and workplace wellness programs; H.R.2846, Planning Actively for Cancer Treatments Act, support coverage of cancer care planning and coordination services; S.91/H.R.4112, Mobile Mammography Promotion Act, issues related to excluding mobile mammography vehicles from the motor fuel excise tax; H.R.3119, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care; S.1488/H.R.2624, Part D Beneficiary Appeals Fairness Act, issues related to out-of-pocket costs for prescription drugs.
Client expense: $38,415 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
2016 · fourth_quarter · Health Issues
Patients' Access to Treatments Act (HR 1600); Cancer Drug Coverage Parity Act (HR 2739, S 1566); 21st Century Cures Act (HR 6); Issues related to patient protections and the Affordable Care Act; Andrea Sloan Compassionate Use Reform & Enhancement Act (HR 909); White House Moonshot Cancer Initiative
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
2016 · fourth_quarter · Health Issues
Patients' Access to Treatments Act (H.R. 1600) Cancer Drug Coverage Parity Act (S. 1566/H.R. 2739) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015 (H.R. 1807) Advancing Hope Act (H.R. 1537/S. 1878) Implementation of Health Reform Legislation/Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage 21st Century Cures Act (H.R. 6, H.R. 34) Innovation for Healthier Americans initiative Issues impacting coverage for hematologic diseases and conditions
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of the Vice President of the United States, SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Health Issues
S. 1566/HR 2739 - Cancer Drug Coverage Parity Act; 21st Century Cures Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
S. 1566/HR 2739 - Cancer Drug Coverage Parity Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Biosimilars - naming (FDA); precision medicine initiative; ACA implementation; clinical trials issues (FDA); HR 2739/S 1566 - Cancer Drug Coverage Parity Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Pharmacy
HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2016 · second_quarter · Health Issues
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Client expense: $740,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Client expense: $820,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
S. 524 Comprehensive Addiction and Recovery Act of 2016 Senate HELP Committee Innovations Package HR 6 21st Century Cures Act HR 1600 Patients Access to Treatment Act of 2015 HR 2739/S 1566 Cancer Drug Coverage Parity Act HR 3381/S 1883 Childhood Cancer STAR Act HR 3119 Palliative Care Hospice Education and Training Act S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015 H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015 S. 2511 Improving Health Information Technology Act Reforms to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
Client expense: $169,982 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.
Client expense: $1,200,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2016 · third_quarter · Insurance
H.R. 30, Save American Workers Act (Young) - definition of full-time employee H.R. 117, Reclaiming Individual Liberty Act (Garrett) - ACA individual mandate H.R. 221, ACA Taxpayer Bailout Prevention Act (Harris) - risk corridors program H.R. 371, Care for All Act (Fortenberry) - catastrophic plans H.R. 494, Competitive Health Insurance Reform Act (Gosar) - antitrust policy H.R. 543, Health Care Choice Act (Blackburn) - national marketplace for individual health insurance H.R. 724, Taxpayer Bailout Protection Act (Lance) - risk corridors program H.R. 815, Access to Independent Health Insurance Advisors Act (Long-Schrader) - treatment of broker compensation in MLR calculation H.R. 954, CO-OP Consumer Protection Act (Smith) - exemption from individual mandate H.R. 1770, Data Security and Breach Notification Act (Blackburn-Welch) - data security H.R. 2205, Data Security Act (Neugebauer) - data security H.R. 2739, Cancer Drug Coverage Parity Act (Lance) - coverage of oral anti-cancer drugs H.R. 2868, Small Business Health Fairness Act (Johnson) - association health plans H.R. 3323, Dental and Optometric Care Access Act (Carter) - dental and vision benefits H.R. 3727, Health Insurance Rate Review Act (Schakowsky) - rate review H.R. 4299, Patient Opportunity Protection Act (Blum) - HIPAA excepted benefits H.R. 5410, Health Coverage State Flexibility Act (Flores) - grace period for recipients of advanced premium tax credits H.R. 5485, Financial Services and General Government Appropriations Act (Crenshaw) - risk corridors amendment H.R. 5589, Plan Verification and Fairness Act (Blackburn) - pre-enrollment verification process H.R. 5921, State Age Rating Flexibility Act (Bucshon) - age rating flexibility H.R. 6019, Relief from Obamacare Mandate Act (Young) - exemption from individual mandate H.R. 6049, Protection from Insurance Exchange Monopolies Act (Heck) - exemption from individual mandate H.R. 5926, FY 2017 Labor-HHS-Education Appropriations Bill (Cole) - ACA risk corridors provision, HHS appropriations H. Res. 887, Public Option (DeFazio) S. 30, Forty Hours Is Full Time Act (Collins) - definition of full-time employee S. 123, ACA Taxpayer Bailout Prevention Act (Rubio) - risk corridors program S. 158, Employee Health Care Protection Act (Cassidy) - grandfathering of health coverage S. 359, Taxpayer Bailout Protection Act (Cassidy) - risk corridors program S. 1099, Protecting Affordable Coverage for Employees Act (Scott-Shaheen) - ACA definition of small employer S. 1532, Affordability is Access Act (Murray) - coverage of OTC birth control S. 1566, Cancer Drug Coverage Parity Act (Kirk) - coverage of oral anti-cancer drugs S. 1661, Access to Independent Health Insurance Advisors Act (Isakson-Coons) - treatment of broker compensation in MLR calculation S. 2172, Health Insurance Rate Review Act (Feinstein) - rate review S. 2803, Taxpayers Before Insurers Act (Sasse) - ACA reinsurance program S. 3296, Protection from ObamaCare Monopolies Act (McCain) - exemption from individual mandate S. 3297, Relief from Obamacare Mandate Act (Cotton) - exemption from individual mandate S. 3326, State Flexibility to Provide Affordable Health Options Act (Alexander) - ACA subsidies, exemption from individual mandate S. Res. 561, Public Option (Merkley) Regulatory Issues: Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; disability income insurance enrollment and awareness; issues related to encouraging impaired workers to stay in/return to the workforce; issues relating to the coordination of benefits between private health insurance plans and Medicaid; Medigap claims processing and crossover fees; Medigap cross-over claim issues, Medigap coverage, implementation of Medigap standardized plan offerings; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials, and other Medigap issues; fraud and abuse issues affecting public and private insurance coverage; issues relating to antitrust; implementation of the Mental Health Parity Act requirements; summary of benefits and coverage disclosures; pre-existing condition insurance plans; accountable care organizations; coverage of preventive services; preexisting condition exclusions; lifetime and annual dollar limits on benefits; patient protections; grandfathered health plan provisions; dependent coverage; treatment of expatriate plans; compliance with the transitional reinsurance program; issues related to fraud, waste, abuse, Stark/Anti-Kickback laws and regulations, non-discriminatory wellness programs; issues related to supplemental products; issues related to implementation of the Telephone Consumer Protection Act; and other issues relating to health care reform implementation.
Client expense: $1,710,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2016 · third_quarter · Health Issues
Patients' Access to Treatments Act (HR 1600); Cancer Drug Coverage Parity Act (HR 2739, S 1566); 21st Century Cures Act (HR 6); PPACA Marketplace plan patient protections; Andrea Sloan Compassionate Use Reform & Enhancement Act (HR 909); Senate Innovation for Healthier Americans Initiative; White House Moonshot Cancer Initiative; FDA Appropriations
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
2016 · third_quarter · Health Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Client expense: $420,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
General FDA issues; S 1566/HR 2739 Cancer Drug Coverage Parity Act; S 3056 CREATES Act; HR 2841 FAST Generics Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the Patient Protection and Affordable Care Act. Policy and implementation issues relating to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the Food and Drug Administration Amendments Act, specifically FDA's Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S. 1566, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Client expense: $570,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Patients' Access to Treatments Act (H.R. 1600) Cancer Drug Coverage Parity Act (S. 1566/H.R. 2739) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015 (H.R. 1807) Advancing Hope Act (H.R. 1537/S. 1878) Resolution expressing support for the designation of the month of September 2016 as "Sickle Cell Disease Awareness Month" (S.Res. 592/H.Res. 903) Implementation of Health Reform Legislation/Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage 21st Century Cures Act (H.R. 6) Innovation for Healthier Americans initiative Issues impacting coverage for hematologic diseases and conditions
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of the Vice President of the United States, SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Health Issues
S. 1566/HR 2739 - Cancer Drug Coverage Parity Act; Cancer moonshot.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Vice President of the U.S.
2016 · third_quarter · Health Issues
Pub. Law No. 111-148, Patient Protection and Affordable Care Act, matters related to the implementation of breast health education, research and clinical trials; S.1566/H.R.2722, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients; H.R.1600, Patients' Access to Treatment Act, support amending the Public Health Service Act to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure and prohibits such a health plan from imposing higher cost-sharing requirements, including co-payment and co-insurance, for specialty drugs than for other prescription drugs in a non-preferred brand drug tier; H.R.1608, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; S.370/H.R.716, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; H.R.1925, Dr. Balazs "Ernie" Bodai Congressional Gold Medal, support the presentation of a congressional gold medal to Dr. Balaz "Ernie" Bodai in recognition of his many outstanding contributions to the nation, including a tireless commitment to breast cancer research; H.R.6, 21st Century Cures Act, issues related to cancer prevention and research funding; S.620/H.R.1189, Preserving Employee Wellness Programs Act, issues related to the Genetic Information Act of 2008 and workplace wellness programs; H.R.2846, Planning Actively for Cancer Treatments Act, support coverage of cancer care planning and coordination services; S.91/H.R.4112, Mobile Mammography Promotion Act, issues related to excluding mobile mammography vehicles from the motor fuel excise tax; H.R.3119, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care; S.1488/H.R.2624, Part D Beneficiary Appeals Fairness Act, issues related to out-of-pocket costs for prescription drugs.
Client expense: $39,585 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
2016 · third_quarter · Health Issues
Biosimilars - naming (FDA); precision medicine initiative; ACA implementation; clinical trials issues (FDA); HR 2739/S 1566 - Cancer Drug Coverage Parity Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
H. Res. 811/ S. Res. 521, recognizing September as Ovarian Cancer Awareness Month; H. 2739/ S. 1566 the Cancer Drug Coverage Parity Act; Activities to support ovarian cancer awareness month related to congressional caucus; Johanna's law implementation.
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
S. 1566/HR 2739 - Cancer Drug Coverage Parity Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · third_quarter · Pharmacy
HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2016 · third_quarter · Health Issues
Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program
Client expense: $6,629 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
HR 2739 / S 1566, the Cancer Drug Coverage Parity Act of 2015 - insurance coverage equality for oral anticancer medications
Client expense: $66,150 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opiod prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments.
Client expense: $1,250,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2016 · second_quarter · Health Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Client expense: $680,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE